Intensity Therapeutics (INTS) Proxy Filing summary

Executive summary

• Special Meeting scheduled for October 22, 2025, to be held virtually to maximize shareholder participation and reduce costs.

• Two key proposals: a reverse stock split authorization and potential adjournment if more votes are needed.

• Board recommends voting in favor of both proposals to maintain Nasdaq listing and flexibility.

Voting matters and shareholder proposals

• Proposal 1: Approve an amendment to effect a reverse stock split at a ratio between 1-for-5 and 1-for-30, with the exact ratio set by the board.

• Proposal 2: Approve adjournment of the meeting if more time is needed to solicit votes for the reverse stock split.

• Both proposals are considered routine, allowing brokers to vote uninstructed shares.

• Board unanimously recommends voting “FOR” both proposals.

Board of directors and corporate governance

• Board retains discretion to implement or abandon the reverse stock split even if approved by shareholders.

• Communication channels are available for shareholders to contact the board or individual directors.